Burden of Cancer an Analysis of Costs Disparities and Strategic Imperatives

Abstract

Issam AW Mohamed

Cancer represents one of the most formidable public health challenges of the 21st century, imposing a profound and escalating burden on individuals, families, healthcare systems, and national economies. This report provides a comprehensive analysis of the multifaceted economic impact of malignant disease, synthesizing extensive data to quantify its scale, deconstruct its core components, and illuminate the stark disparities in its distribution. A landmark modeling study projects that the global macroeconomic cost of 29 major cancers will reach an astonishing $25.2 trillion (in constant 2017 international dollars) between 2020 and 2050, a figure equivalent to a persistent 0.55% annual tax on the world's Gross Domestic Product (GDP). This immense financial toll is not an abstract calculation but a tangible drag on global prosperity, driven by a complex interplay of direct healthcare expenditures, the escalating price of innovative therapies, and vast societal losses in productivity. The analysis reveals that this burden is highly concentrated, with five cancer types—tracheal, bronchus, and lung; colorectal; breast; liver; and leukemia—accounting for nearly half of the total global economic cost. The financial impact is also distributed with profound inequity. High-income countries (HICs) face the largest absolute costs, driven by expensive treatments and high labor valuations, with North America, Europe, and East Asia shouldering over 85% of the global burden. Conversely, low- and middle-income countries (LMICs), where approximately 75% of cancer deaths occur, face a crisis of access and a devastating human toll, with productivity losses from premature mortality crippling developing economies.

PDF